General Anesthesia Drugs

General Anesthesia Drugs

Global General Anesthesia Drugs Market to Reach US$9.8 Billion by 2030

The global market for General Anesthesia Drugs estimated at US$7.8 Billion in the year 2023, is expected to reach US$9.8 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Propofol, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Sevoflurane segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 4.8% CAGR

The General Anesthesia Drugs market in the U.S. is estimated at US$2.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global General Anesthesia Drugs Market - Key Trends and Drivers Summarized

Why Are General Anesthesia Drugs Essential in Modern Surgery and Medical Procedures?

General anesthesia drugs are critical in modern surgery and medical procedures, allowing patients to undergo complex and often invasive operations without pain, discomfort, or awareness. But why are these drugs so essential today? General anesthesia induces a reversible state of unconsciousness, pain relief, muscle relaxation, and amnesia, making it possible for surgeons to perform intricate procedures without causing distress or physical harm to the patient. From routine surgeries to life-saving operations, general anesthesia ensures that patients remain unaware and pain-free throughout the procedure, contributing to the success and safety of modern medicine.

These drugs are used in a wide variety of medical settings, including major surgeries like heart bypass, organ transplants, and orthopedic operations, as well as in diagnostic procedures such as colonoscopies or biopsies that require patients to remain still for extended periods. Anesthesiologists tailor the administration of general anesthesia to each patient, taking into account factors like age, weight, health conditions, and the nature of the surgery to ensure the correct balance of drugs for safe and effective sedation. The ability to control consciousness, pain, and bodily functions is vital for surgical precision, allowing healthcare professionals to focus entirely on the task at hand without concerns over patient movement or discomfort.

How Are Technological Advancements Improving the Safety and Precision of General Anesthesia Drugs?

Technological advancements are significantly enhancing the safety, precision, and overall administration of general anesthesia drugs, ensuring better patient outcomes and reducing the risks associated with anesthesia. One of the most impactful developments is the introduction of advanced monitoring systems that allow anesthesiologists to closely track a patient’s vital signs, including heart rate, oxygen levels, blood pressure, and brain activity during surgery. These real-time monitoring systems provide critical feedback on how the patient is responding to the anesthesia, enabling healthcare providers to adjust drug dosages in real time to maintain the ideal depth of anesthesia. This technology helps prevent complications like under- or over-sedation, which can lead to awareness during surgery or adverse side effects.

Another important advancement is the development of shorter-acting anesthetic agents that offer greater control over sedation levels and quicker recovery times. Modern anesthetics such as propofol, sevoflurane, and desflurane have become widely used because they allow for rapid induction and emergence from anesthesia. These agents provide greater precision in controlling the duration of anesthesia, reducing the risks of prolonged recovery and post-operative complications like nausea, vomiting, or cognitive impairment. Faster recovery times are especially beneficial in outpatient surgeries, where patients need to regain consciousness and stability quickly after a procedure.

The rise of pharmacogenomics—the study of how genes affect a person’s response to drugs—also plays a role in the evolution of anesthesia. Anesthesiologists can now use genetic data to predict how a patient will metabolize specific anesthesia drugs, allowing for more personalized dosing strategies. This reduces the likelihood of adverse reactions and ensures that each patient receives the most effective and safest anesthetic plan tailored to their unique genetic makeup. Additionally, advancements in drug delivery systems, such as target-controlled infusion (TCI) pumps, offer more precise control over the rate at which anesthesia drugs are administered, improving accuracy and reducing the risk of overdose or complications.

With these advancements in monitoring, drug formulations, genetic insight, and delivery systems, the administration of general anesthesia has become safer, more efficient, and better tailored to the needs of individual patients, greatly improving the overall quality of care.

Why Are General Anesthesia Drugs Crucial for Patient Safety and Comfort During Surgery?

General anesthesia drugs are fundamental to ensuring patient safety and comfort during surgery, as they provide complete pain relief, unconsciousness, and muscle relaxation. One of the most important roles of general anesthesia is to prevent pain during invasive procedures. Without these drugs, patients would experience unbearable pain, which could lead to trauma, shock, and significant physiological stress during surgery. General anesthetics block the perception of pain by inhibiting the central nervous system’s ability to process pain signals, ensuring that patients remain pain-free throughout the procedure.

Additionally, general anesthesia induces a state of unconsciousness, allowing surgeons to perform complex and lengthy surgeries without causing distress to the patient. The drugs used in general anesthesia also include muscle relaxants, which are particularly important in surgeries requiring precision and immobility, such as orthopedic or neurosurgical procedures. By relaxing the patient’s muscles, anesthetics prevent involuntary movements that could interfere with the surgeon’s work, enhancing the safety and success of the operation.

Post-operative care is also improved by general anesthesia, as the drugs typically include agents that cause amnesia, meaning patients have no recollection of the surgery or the discomfort that might have been involved. This lack of awareness during surgery helps reduce the risk of psychological trauma associated with invasive procedures. Moreover, by ensuring complete sedation, general anesthesia reduces the physiological stress on the body, including the cardiovascular and respiratory systems, which could otherwise be compromised during major surgery. This controlled environment is essential for patient safety, especially for those with pre-existing medical conditions or undergoing high-risk surgeries.

Overall, the role of general anesthesia is not only to ensure that patients are comfortable and pain-free but also to create a stable physiological environment where the surgery can be performed safely and effectively. It is a vital component of modern surgical care, allowing for greater precision, fewer complications, and better patient outcomes.

What Factors Are Driving the Growth of the General Anesthesia Drugs Market?

The general anesthesia drugs market is experiencing significant growth, driven by several key factors, including the rising number of surgical procedures, advancements in drug formulations, and an increasing focus on patient safety and recovery. First, the global rise in surgical procedures, including elective, emergency, and outpatient surgeries, is a major driver of the anesthesia drugs market. As healthcare infrastructure improves, particularly in developing regions, access to surgical care is expanding, leading to an increased demand for anesthesia services. Additionally, the aging population and higher incidence of chronic diseases such as cardiovascular issues, cancer, and orthopedic problems are contributing to the growth of surgeries, further boosting the need for general anesthesia drugs.

Second, advancements in anesthetic drug formulations are driving market growth. The development of newer anesthetic agents, such as propofol, sevoflurane, and remifentanil, has made general anesthesia safer, more efficient, and better tolerated by patients. These drugs offer rapid onset and recovery, reduced side effects, and better control over sedation depth, making them ideal for a wide range of surgical procedures. The increasing preference for minimally invasive surgeries, which require shorter-acting anesthetics, is also contributing to the demand for advanced general anesthesia drugs that allow for quicker patient recovery and shorter hospital stays.

Third, the growing emphasis on patient safety and enhanced recovery protocols is boosting the market for general anesthesia drugs. Healthcare providers are focusing on reducing post-operative complications and improving patient outcomes through the use of tailored anesthesia regimens. Enhanced Recovery After Surgery (ERAS) protocols, which aim to minimize the physical stress of surgery, often incorporate modern anesthetic agents that facilitate quicker recovery and reduce the risk of post-operative nausea, vomiting, and cognitive dysfunction. The demand for these advanced anesthesia solutions is driving market growth as hospitals and surgical centers adopt best practices in patient care.

Additionally, the expansion of outpatient and ambulatory surgery centers is fueling the demand for general anesthesia drugs. As more surgeries shift to outpatient settings, where patients are discharged the same day, there is a growing need for anesthesia drugs that offer rapid recovery times and minimal side effects. Outpatient procedures such as cataract surgeries, endoscopies, and cosmetic surgeries rely on short-acting anesthetics that allow patients to regain consciousness quickly and recover without the need for extended hospitalization.

Lastly, rising healthcare spending and technological advancements in anesthesia delivery systems, such as target-controlled infusion (TCI) devices and advanced monitoring technologies, are also contributing to market growth. These innovations ensure safer, more precise administration of anesthesia drugs, further enhancing patient safety and driving demand for newer, more effective anesthetic agents.

In conclusion, the growth of the general anesthesia drugs market is driven by the increasing number of surgeries, advancements in anesthetic drug formulations, a focus on patient safety, and the expansion of outpatient surgical care. As healthcare providers continue to prioritize improved surgical outcomes and faster recovery times, the demand for high-quality general anesthesia drugs is expected to rise, ensuring the continued expansion of this essential market.

Select Competitors (Total 43 Featured) -
  • Abbott Laboratories
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Hospira, Inc.
  • Novartis AG
  • Pfizer, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
General Anesthesia Drugs – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Number of Surgical Procedures Globally Drives Demand for General Anesthesia Drugs
Rising Prevalence of Chronic Diseases Necessitates More Complex Surgeries
Growing Geriatric Population and the Increasing Need for Surgical Interventions
Development of Ultra-Short Acting Anesthetics Improves Patient Recovery Time
Expanding Applications in Veterinary Surgeries Propel Market Expansion
Advances in Monitoring Technologies for Anesthesia Administration
Expansion of Ambulatory Surgery Centers Boosts Short-acting Anesthetic Use
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World General Anesthesia Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for General Anesthesia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for General Anesthesia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for General Anesthesia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Propofol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Propofol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Propofol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Sevoflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Sevoflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Sevoflurane by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Remifentanil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Remifentanil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Remifentanil by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Dexmedetomidine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Dexmedetomidine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Dexmedetomidine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Desflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Desflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Desflurane by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Isoflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Isoflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Isoflurane by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Midazolam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Midazolam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Midazolam by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: World 16-Year Perspective for Inhalation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 35: USA Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: USA Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: USA 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: USA Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: USA 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
CANADA
TABLE 41: Canada Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Canada Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Canada 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 44: Canada Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Canada Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Canada 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
JAPAN
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 47: Japan Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Japan Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Japan 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 50: Japan Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Japan Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Japan 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
CHINA
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 53: China Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: China Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: China 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 56: China Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: China Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: China 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
EUROPE
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 59: Europe Recent Past, Current & Future Analysis for General Anesthesia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for General Anesthesia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for General Anesthesia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 62: Europe Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Europe Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Europe 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 65: Europe Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Europe Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Europe 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
FRANCE
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 68: France Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: France Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: France 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 71: France Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: France Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: France 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
GERMANY
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 74: Germany Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Germany Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Germany 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 77: Germany Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Germany Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Germany 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
ITALY
TABLE 80: Italy Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Italy Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Italy 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 83: Italy Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Italy Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Italy 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
UNITED KINGDOM
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 86: UK Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: UK Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: UK 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 89: UK Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: UK Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: UK 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
SPAIN
TABLE 92: Spain Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Spain Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Spain 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 95: Spain Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Spain Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Spain 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
RUSSIA
TABLE 98: Russia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Russia Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Russia 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 101: Russia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Russia Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Russia 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Rest of Europe Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Rest of Europe 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Rest of Europe Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Rest of Europe 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
ASIA-PACIFIC
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for General Anesthesia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for General Anesthesia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for General Anesthesia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Asia-Pacific Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Asia-Pacific 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Asia-Pacific Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Asia-Pacific 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
AUSTRALIA
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 119: Australia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: Australia Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: Australia 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 122: Australia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Australia Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: Australia 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
INDIA
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 125: India Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: India Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: India 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 128: India Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: India Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: India 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 131: South Korea Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: South Korea Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: South Korea 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 134: South Korea Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: South Korea Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: South Korea 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Rest of Asia-Pacific Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Rest of Asia-Pacific 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of Asia-Pacific Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Rest of Asia-Pacific 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
LATIN AMERICA
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 143: Latin America Recent Past, Current & Future Analysis for General Anesthesia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for General Anesthesia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for General Anesthesia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 146: Latin America Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Latin America Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Latin America 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 149: Latin America Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Latin America Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Latin America 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 152: Argentina Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Argentina Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Argentina 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 155: Argentina Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Argentina Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Argentina 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
BRAZIL
TABLE 158: Brazil Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Brazil Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Brazil 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 161: Brazil Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Brazil Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Brazil 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
MEXICO
TABLE 164: Mexico Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Mexico Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Mexico 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 167: Mexico Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Mexico Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Mexico 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Rest of Latin America Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Rest of Latin America 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Rest of Latin America Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Rest of Latin America 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
MIDDLE EAST
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 176: Middle East Recent Past, Current & Future Analysis for General Anesthesia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for General Anesthesia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for General Anesthesia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 179: Middle East Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Middle East Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Middle East 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 182: Middle East Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Middle East Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Middle East 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
IRAN
TABLE 185: Iran Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Iran Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Iran 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 188: Iran Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Iran Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Iran 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
ISRAEL
TABLE 191: Israel Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Israel Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Israel 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 194: Israel Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Israel Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Israel 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Saudi Arabia Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Saudi Arabia 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Saudi Arabia Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Saudi Arabia 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 203: UAE Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: UAE Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: UAE 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 206: UAE Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: UAE Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: UAE 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Rest of Middle East Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Rest of Middle East 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Rest of Middle East Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Rest of Middle East 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
AFRICA
General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 215: Africa Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 216: Africa Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 217: Africa 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
TABLE 218: Africa Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 219: Africa Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 220: Africa 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings